Holen Sie sich die Stockscreener-App
34.01
1.04%
0.38
Schlusskurs vom Vortag:
$33.63
Offen:
$33.61
24-Stunden-Volumen:
240.88K
Relative Volume:
0.13
Marktkapitalisierung:
$20.94B
Einnahmen:
$2.62B
Nettoeinkommen (Verlust:
$966.70M
KGV:
22.67
EPS:
1.5004
Netto-Cashflow:
$1.09B
1W Leistung:
+6.79%
1M Leistung:
+9.86%
6M Leistung:
+57.46%
1J Leistung:
+53.13%
1-Tages-Spanne:
$33.57
$34.03
1-Wochen-Bereich:
$31.29
$33.99
52-Wochen-Spanne:
$17.23
$33.99
Genmab Adr Stock (GMAB) Company Profile
Vergleichen Sie GMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
34.00 | 20.72B | 2.62B | 966.70M | 1.09B | 1.5004 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.96 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
818.57 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.25 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.40 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
338.41 | 35.45B | 4.98B | 69.59M | 525.67M | 0.5197 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-01 | Herabstufung | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-12-06 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
| 2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Eingeleitet | BTIG Research | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-31 | Eingeleitet | UBS | Neutral |
| 2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
| 2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-05-02 | Eingeleitet | Cowen | Market Perform |
| 2022-03-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-12-01 | Eingeleitet | Berenberg | Sell |
| 2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
Genmab A/S (NASDAQ:GMAB) Shares Down 3.5% – Here’s Why - Defense World
Genmab A/S (NASDAQ:GMAB) Stock Price Down 3.5%Time to Sell? - MarketBeat
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus - TechStock²
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Genmab Portfolio Prioritization Update - GlobeNewswire
Genmab–BioNTech cancer antibody trial ends early: What investors need to know - MSN
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know - TipRanks
Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN
Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year HighStill a Buy? - MarketBeat
Quoin Pharm ADR clears technical benchmark, hitting 90-plus RS rating - MSN
Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN
Squarepoint Ops LLC Has $1.95 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
China Universal Asset Management Co. Ltd. Has $381,000 Stake in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - GlobeNewswire Inc.
Pipeline of Proprietary Antibodies - flow – Deutsche Bank
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 86,842 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by First Trust Advisors LP - Defense World
Quoin Pharm ADR Joins Rank Of Stocks With RS Ratings Over 90 - MSN
Marshall Wace LLP Cuts Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by American Century Companies Inc. - Defense World
AI Plays Lead Five Stocks To Watch Near Buy Points - Investor's Business Daily
Arrowstreet Capital Limited Partnership Raises Position in Genmab A/S Sponsored ADR $GMAB - Defense World
JPMorgan Chase & Co. Grows Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter - Investor's Business Daily
Genmab A/S Sponsored ADR $GMAB Position Reduced by Russell Investments Group Ltd. - MarketBeat
Capital Fund Management S.A. Has $4.68 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arbor Realty Trust Inc (ABR): What is the Risk Factor? - fostersleader.com
Level Four Advisory Services LLC Acquires 12,888 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR Earns Membership In 95-Plus Composite Rating Club - MSN
Rockefeller Capital Management L.P. Purchases New Shares in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Creative Planning - Defense World
AlphaCore Capital LLC Invests $44,000 in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR $GMAB Shares Sold by PNC Financial Services Group Inc. - MarketBeat
AIMZ Investment Advisors LLC Has $3.43 Million Position in Genmab A/S Sponsored ADR $GMAB - Defense World
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Vera Therapeutics Stock Earns RS Rating Upgrade - Investor's Business Daily
Q1 Earnings Estimate for Genmab A/S Issued By HC Wainwright - Defense World
Ocular Therapeutix Stock Earns 81 RS Rating - Investor's Business Daily
FY2025 EPS Estimates for Genmab A/S Raised by HC Wainwright - Defense World
Syndax Pharmaceuticals Stock Earns RS Rating Upgrade - Investor's Business Daily
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genmab Adr-Aktie (GMAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
2,978 |
288,866 |
72,831,487 |
| GENMAB A/S | 10% Owner |
Dec 23 '25 |
Buy |
97.00 |
561,042 |
54,421,074 |
72,589,817 |
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
142,610 |
13,833,170 |
72,828,509 |
| GENMAB A/S | 10% Owner |
Dec 24 '25 |
Buy |
97.00 |
96,082 |
9,319,954 |
72,685,899 |
| GENMAB A/S | 10% Owner |
Dec 22 '25 |
Buy |
97.00 |
15,710 |
1,523,870 |
72,028,775 |
| GENMAB A/S | 10% Owner |
Dec 18 '25 |
Buy |
97.00 |
212,177 |
20,581,169 |
71,946,801 |
| GENMAB A/S | 10% Owner |
Dec 19 '25 |
Buy |
97.00 |
66,264 |
6,427,608 |
72,013,065 |
| GENMAB A/S | 10% Owner |
Dec 17 '25 |
Buy |
97.00 |
150,795 |
14,627,115 |
71,734,624 |
| GENMAB A/S | 10% Owner |
Dec 16 '25 |
Buy |
97.00 |
120,752 |
11,712,944 |
71,583,829 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):